Impact of prior lenalidomide or proteasome inhibitor exposure on the effectiveness of ixazomib-lenalidomide-dexamethasone for relapsed/refractory multiple myeloma: A pooled analysis from the INSURE study.
Journal article
Lee HC. et al, (2024), Eur J Haematol
Challenges in designing and running smouldering myeloma interventional clinical trials.
Journal article
Lecat C. et al, (2024), EJHaem, 5, 418 - 420
Adjusting for subsequent therapies in the TOURMALINE-MM1 study shows clinically meaningful improvement in overall survival with addition of ixazomib to lenalidomide and dexamethasone.
Journal article
Ramasamy K. et al, (2024), Haematologica
Diagnosis and management of smouldering myeloma: A British Society for Haematology Good Practice Paper.
Journal article
Hughes D. et al, (2024), Br J Haematol
Longitudinal dynamics and clinically available predictors of poor response to COVID-19 vaccination in multiple myeloma.
Journal article
Agarwal G. et al, (2024), Haematologica
INSURE: a pooled analysis of ixazomib-lenalidomide-dexamethasone for relapsed/refractory myeloma in routine practice.
Journal article
Leleu X. et al, (2024), Future Oncol
Real-world treatment patterns in patients initiating third-line therapy for relapsed or refractory multiple myeloma in Germany, Italy, the United Kingdom, France, and Spain.
Journal article
Lehne M. et al, (2023), Eur J Haematol
Determinants of durable humoral and T cell immunity in myeloma patients following COVID-19 vaccination.
Journal article
Twumasi C. et al, (2023), Eur J Haematol
Multiple myeloma and its treatment contribute to increased platelet reactivity.
Journal article
Mitchell JL. et al, (2023), Platelets, 34
Use Via Early Access to Ixazomib (UVEA-IXA) Study: Effectiveness and Safety of Ixazomib-based Therapy in Relapsed/Refractory Multiple Myeloma Outside of the Clinical Trial Setting.
Journal article
Ludwig H. et al, (2023), Clin Lymphoma Myeloma Leuk
Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma.
Journal article
Richardson PG. et al, (2023), N Engl J Med, 389, 1009 - 1022
Measurable Residual Disease Testing in Multiple Myeloma Routine Clinical Practice: A Modified Delphi Study.
Journal article
Ramasamy K. et al, (2023), Hemasphere, 7
Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel.
Journal article
Raje N. et al, (2023), Blood Cancer J, 13
P864: A PHASE 1 STUDY OF BELANTAMAB MAFODOTIN IN COMBINATION WITH STANDARD OF CARE IN NEWLY DIAGNOSED MULTIPLE MYELOMA: AN INTERIM ANALYSIS OF DREAMM-9
Journal article
Usmani SZ. et al, (2023), HemaSphere, 7
P868: MEZIGDOMIDE (MEZI) PLUS DEXAMETHASONE (DEX) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM THE DOSE-EXPANSION PHASE OF THE CC-92480-MM-001 TRIAL
Journal article
Bahlis NJ. et al, (2023), HemaSphere, 7
P945: REAL-WORLD CLINICAL OUTCOMES AMONG TRIPLE-CLASS EXPOSED RELAPSED REFRACTORY MULTIPLE MYELOMA PATIENTS IN US AND EUROPE: A PREAMBLE REGISTRY STUDY
Journal article
Ramasamy K. et al, (2023), HemaSphere, 7
P1362: DEVELOPMENT OF A NOVEL ONCOLYTIC VIRUS -THEO-310 - SPECIALISED FOR TARGETING THE BONE MARROW TUMOUR MICROENVIRONMENT OF MULTIPLE MYELOMA PATIENTS
Journal article
Bamford R. et al, (2023), HemaSphere, 7
Léčba pacientů s mnohočetným myelomem po expozici lenalidomidu a postavení přípravku Ninlaro v terapeutické sekvenci
Journal article
Ramasamy K., (2023), Onkologie (Czech Republic), 17, 209 - 214
P16 HEALTH-RELATED QUALITY OF LIFE FOR FRAIL TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH DARATUMUMAB, LENALIDOMIDE AND DEXAMETHASONE: SUBGROUP ANALYSIS OF MAIA TRIAL
Journal article
Facon T. et al, (2023), HemaSphere, 7
Correction: Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma.
Journal article
Kurata K. et al, (2023), Blood Cancer J, 13